Understand the source comparison
SS-LUP-332 vs Other Metabolic Research Compounds: Mechanism Comparison
The table below maps SS-LUP-332 science explained against four widely studied metabolic compounds, highlighting mechanism of action, primary metabolic effect, tissue selectivity, and clinical translation status as of 2026. SS-LUP-332 Direct AMPK gamma subunit
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below maps SS-LUP-332 science explained against four widely studied metabolic compounds, highlighting mechanism of action, primary metabolic effect, tissue selectivity, and clinical translation status as of 2026.
- SS-LUP-332
- Direct AMPK gamma subunit activation → PGC-1α upregulation
- Mitochondrial biogenesis, insulin-independent glucose uptake, fatty acid oxidation
- High. Adipose lipolysis, muscle mitochondrial density preserved
- Preclinical. Rodent models only
- Best option for metabolic correction without appetite suppression; requires baseline mitochondrial dysfunction to show maximal effect
- Metformin
- Mitochondrial complex I inhibition → indirect AMPK activation
- Reduced hepatic gluconeogenesis, modest insulin sensitization
- Moderate. Hepatic > muscle > adipose
- FDA-approved for T2DM (1994)
- Gold standard for glycemic control but GI intolerance in 25–30%; weaker mitochondrial effect than direct AMPK activators
- Semaglutide (GLP-1)
- GLP-1 receptor agonist → delayed gastric emptying, central appetite suppression
- Weight loss via reduced caloric intake, improved postprandial insulin
- Low. Systemic appetite suppression affects all tissues equally
- FDA-approved for obesity (Wegovy, 2021)
- Most effective weight loss pharmacotherapy available but mechanism is caloric restriction, not metabolic correction; high nausea rate during titration
- Tesofensine
- Triple monoamine reuptake inhibitor (dopamine, norepinephrine, serotonin)
- Increased energy expenditure, appetite suppression, thermogenesis
- Moderate. CNS-driven; peripheral effects secondary
- Phase III completed; not FDA-approved as of 2026
- Potent but CNS side effects (increased heart rate, insomnia) limit tolerability; combines well with mitochondrial activators in research models
- DNP (2,4-Dinitrophenol)
- Mitochondrial uncoupler. Dissipates proton gradient as heat
- Extreme thermogenesis, indiscriminate fat and muscle catabolism
- None. Affects all mitochondria systemically
- Banned for human use (1938); research use only under strict containment
- Highest thermogenic potency but lethal dose is 2–3× therapeutic dose; zero margin for error; used only in controlled metabolic research